1. Charakterystyka patogenu i epidemiologia zakażeń. 2. Objawy chorobowe i źródła zakażeń. 3. Szczepionki anty-Campylobacter. 4. Podjednostkowe szczepionki anty-Campylobacter skonstruowane z użyciem atenuowanych szczepów S.enterica. 5. Podsumowanie
Abstract: Campylobacter jejuni is currently recognized as a major cause of food-borne human gastroenteritis worldwide. In developed countries the majority of Campylobacter infections are associated with the consumption of undercooked poultry meat. Although a disease lasts only several days and is very often self-limiting, campylobacteriosis constitutes a serious medical and socioeconomic problem. In patients, especially from developed countries, who have not encountered the pathogen before the infection can result in severe gastroenteritis accompanied with long-lasting bloody or mucus diarrhea. Moreover, C. jejuni can cause septicemia in immunocompromised individuals or induce autoimmune neurological disorders. Rapidly increasing antibiotic resistance of Campylobacter strains compels us to develop alternative therapeutic strategies. Implementation of immunoprophylaxis for humans or chickens seems to be the most effective strategy to decrease the number of human infections. Subunit vaccines are the safest, but mildly immunogenic, prophylactic method therefore, heterologous antigens are frequently delivered to a host by special delivery vectors i.e. attenuated Salmonella strains, to induce protective immune response. Avirulent Salmonella strains were also successfully used as a carrier to construct anti-Campylobacter subunit vaccines. Up till now, only several Campylobacter genes encoding immunogenic proteins: Peb1A, CjaA, Pal, Cj0420 and bacterioferritin, were cloned in Salmonella cells and the immune response and protection efficiency of constructed vaccine were determined on animal models. Here, we discuss the recent developments in the field of Salmonella-based anti-Campylobacter vaccines.
1. Pathogen characteristics and infection epidemiology. 2. The symptoms and source of infections. 3. Anti-Campylobacter vaccines. 4. Anti-Campylobacter subunit vaccines constructed with attenuated S.enterica cells. 5. Conclusions